

27 November 2024

Dear Shareholder

SHARE PURCHASE PLAN – ACCESS LETTER

ADELAIDE, 27 November 2024: Anatara Lifesciences (ASX: ANR or “the Company”), a developer of evidence-based solutions for gastrointestinal diseases in humans, is pleased to offer Eligible Shareholders (defined below) the opportunity to apply for up to A\$30,000 worth of fully paid ordinary shares in the Company (**Shares**) (without incurring brokerage or other transaction costs) under the terms and conditions of a share purchase plan (**SPP Offer**) following the capital raise announcement on the 15th of November 2024. The issue price of the Shares under the Offer (**SPP Shares**) will be A\$0.05 per SPP Share.

The terms and conditions of the SPP Offer detailed in the offer booklet released to the ASX today (**SPP Offer Booklet**). Details can also be found on the Company's website at www.anataralifesciences.com. The SPP Offer is made in accordance with ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547 and therefore does not require a prospectus for the purposes of Chapter 6D of the *Corporations Act 2001* (Cth) (**Corporations Act**).

Further details on how to apply and participate under the SPP Offer are set out below.

SPP Offer

The SPP Offer is offered exclusively to eligible shareholders (including custodians), being registered holders of Shares as at 7:00pm (AEDT) on Tuesday, 14 November 2024 (**Record Date**) with a registered address in Australia or New Zealand and not resident or located in the United States or any other jurisdiction in or into which an offer of SPP Shares would be unlawful (**Eligible Shareholders**).

Eligible Shareholders may apply for SPP Shares ranging from a minimum value of A\$2,000 up to a maximum value of A\$30,000 (subject to scale back).

The Company intends to raise A\$0.5 million (before costs) through the issue of SPP Shares under the SPP Offer. The Company may at its discretion accept oversubscriptions. If total demand for the SPP Offer exceeds \$0.5 million, the Directors may in their absolute discretion undertake a scale back to the extent and in the manner they see fit. The factors which the Directors may take into account in determining any scale back are contained in the SPP Offer Booklet.

The SPP Offer opens at 9:00am (AEDT) on Wednesday, 27 November 2024 and is currently scheduled to close at 5:00pm (AEDT) on Wednesday, 18 December 2024 (Closing Date). The SPP Shares are expected to be issued and commence trading on the ASX on



Tuesday, 24 December 2024 and will, upon their issue, rank equally in all respects with the Company's existing Shares on issue.

Eligible Shareholders wishing to participate in the SPP Offer must make payment via BPAY® (for holders of an account with an Australian financial institution that supports BPAY® transactions) or Electronic Funds Transfer (**EFT**) by 5:00pm (AEDT) on the Closing Date. The Company reserves the right, subject to the Corporations Act and the ASX Listing Rules, to vary the Closing Date without prior notice including closing the SPP Offer early or extending the Closing Date. If the Closing Date is varied, subsequent dates may also be varied accordingly. The Company therefore encourages any Eligible Shareholders (including custodians) wishing to participate in the SPP Offer to remit their application monies as soon as possible.

Application Procedure

This letter is to notify you that the SPP Offer is now open and provide you with instructions as to how to obtain a copy of the SPP Offer Booklet and your personalised application form (Application Form).

The Company will not be printing / dispatching hard copies of the SPP Offer Booklet or Application Forms, unless requested by an Eligible Shareholder.

How to obtain a copy of the SPP Offer Booklet and your Application Form:

Online: The SPP Offer Booklet and your personalised Application Form (including how to pay by BPAY®) can be accessed online at www.computersharecas.com.au/anrspp.

For New Zealand Shareholders - Pay via EFT

New Zealand based Shareholders without an Australian Bank account will not be able to pay via BPAY® and will instead need to make payment via EFT. New Zealand based Shareholders can make an EFT payment to the bank account specified on the EFT instructions accompanying the SPP Application Form available at www.investorcentre.com.

Paper: If you are unable to access your Application Form online, you can request a paper copy of the SPP Offer Booklet and your personalised Application Form by calling the Company on +61 (0) 411712579 or +61 (0) 408326367 between 8:30am and 5:00pm (AEDT) Monday to Friday (excluding public holidays). To accept the SPP Offer using these paper copy documents, you will still need to make payment via BPAY® (Australian applicants) or EFT (Overseas applicants).



You should read the SPP Offer Booklet (together with the Application Form) carefully and in its entirety prior to making an application under the SPP Offer. Your application under the SPP Offer must be made by making payment via BPAY® or EFT in accordance with the personalised payment instructions on your Application Form.

If you make a payment by BPAY® or EFT, you do not need to return the Application Form but are taken to have made the declarations on the Application Form.

Use of Funds

Funds raised from the Placement and the SPP will be used to finish the pivotal Phase II clinical study of Anatara's GaRP (*Gastrointestinal ReProgramming*) complementary medication for irritable bowel syndrome (IBS) and to further readiness for manufacturing.

There will also be approximately \$250,000 allocated to an anti-obesity proof of concept project. The anti-obesity project has been designed to develop an oral medication to assist weight reduction and sustaining weight control in conjunction with other contemporary treatments and approaches.

Key Dates

The key dates for the Placement and SPP are as follows:

Record Date (for the SPP)	7:00 p.m. (AEDT) on Thursday 14 November 2024
Announcement of Placement and SPP and recommencement of trading of Shares on the ASX	Friday 15 November 2024
Settlement of Placement Shares	Thursday 21 November 2024
Issue of Placement Shares	Friday 22 November 2024
Despatch of SPP Offer Booklet	Wednesday 27 November 2024
SPP Opens	9.00 a.m. (AEDT) on Wednesday 27 November 2024
SPP closes	5.00 p.m. (AEDT) on Wednesday 18 December 2024
Results of SPP announced to the ASX	Monday 23 December 2024
Issue of Shares under the SPP	Monday 23 December 2024



Note: The timetable is indicative only and subject to change. The Company reserves the right, subject to compliance with the Corporations Act and the ASX Listing Rules, to vary the Closing Date without prior notice including to extend the Closing Date or close the SPP Offer early. If the Closing Date is varied, subsequent dates may also be varied accordingly. Any changes will be advised to shareholders. The SPP shares are expected to be issued on Monday 23 December 2024 and commence trading on the ASX on Tuesday 24 December 2024 and will, upon their issue, rank equally in all respects with the Company's existing Shares on issue.

Summary of Share Purchase Plan

Anatara will give eligible shareholders an opportunity to subscribe for new fully paid ordinary shares (**SPP Shares**) in Anatara by way of an SPP. The issue price of the SPP Shares will be same as the recent Placement i.e. \$0.05 per share.

Under the SPP, each shareholder who held shares in Anatara at 7:00 p.m. (AEDT) on Thursday 14 November 2024 and who has a registered address in Australia or New Zealand will be entitled to acquire up to \$30,000 of SPP Shares without brokerage. The SPP will raise a target amount of \$500,000 (before costs) with the ability to accept over subscriptions, noting the cap of \$30,000 of SPP Shares for each shareholder.

Anatara Directors, that hold Shares, may participate in the SPP.

Full details of the SPP (including details of any scale back in the event of oversubscription) will be set out in the SPP Offer Booklet which is expected to be released to ASX and despatched to eligible shareholders on Wednesday 27 November 2024.

Eligible Shareholders may apply for SPP Shares in parcels of Shares with a dollar value of \$2,000, \$3,000, \$4,000, \$5,000, \$7,500, \$10,000, \$15,000, \$20,000, \$25,000 or a maximum of \$30,000.

Further Information

If you have any questions in relation to the SPP Offer, please contact the Company on +61 (0) 411712579 or +61 (0) 408326367 between 8:30am and 5:00pm (AEDT) Monday to Friday (excluding public holidays) during the offer period for the SPP Offer or email the Company Secretary at info@anatara.com. For other questions, you should consult your broker, solicitor, accountant, financial adviser, or other professional adviser.



For more information please contact:

Dr. David Brookes
Chair
Anatara Lifesciences Ltd
+61 (0) 411 712 579
dbrookes@anatara.com

Dirk van Dissel
Candour Advisory
Investor Relations
+61 (0) 408 326 367
dirk@candouradvisory.com.au

About Anatara Lifesciences Ltd

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based health products where there is significant unmet need. Anatara is focused on building a pipeline of human health products with a particular focus on conditions that involve the complexity of the gastrointestinal tract. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

Anatara Lifesciences Limited
Registered Office
C/-PERKS Level 8, 81 Flinders Street, Adelaide SA 5000
Email info@anatara.com | Website anataralifesciences.com
ABN 41 145 239 872

